University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Prostate Cancer Disparities Greatest in Low-Risk Disease

New UCSF Study Analyzes Prostate Cancer Deaths by Race

By UCSF.edu | December 19, 2018

Prostate Cancer Disparities Greatest in Low-Risk Disease

Black men in the United States are known to suffer disproportionately from prostate cancer. Now, a new study investigating prostate cancer deaths by race has found that African American men have twice the chance of dying from low-risk prostate cancer than men of other racial and ethnic groups, even after adjusting for socioeconomic status. 

The study, led by UC San Francisco, raises intriguing questions about whether the biology of low-risk prostate cancer in black men is distinct from that of other ethnicities. 

The research appears in JAMA, the Journal of the American Medical Association

 “This study suggests we need more research on the factors that may make low-risk prostate cancer more deadly in black men,” said Franklin W. Huang, MD, PhD, a UCSF assistant professor of medicine whose research uses cancer genomics and centers on prostate cancer in African American men and underserved cancer patients. Huang’s laboratory research focuses on identifying the biological features of tumors that drive cancer disparities.

African American men have a 15 percent chance of developing prostate cancer, compared to 10 percent for white men, according to the National Cancer Institute. In addition, the risk of dying from prostate cancer for African American men is about 4 percent compared to about 2 percent for white men.

The new study investigated prostate cancer mortality by race and by Gleason score, the latter of which is considered the best independent predictor of prostate cancer outcomes. A Gleason score of 6 indicates low-grade disease and a Gleason score of 7 to 10 indicates intermediate- to high-grade disease. The researchers analyzed data from Surveillance, Epidemiology and End Results (SEER) at two points: 36 months after prostate cancer diagnosis (192,224 men) and 65 months after diagnosis (403,022 men).

They found that for both timeframes, black patients with prostate cancer were younger than nonblack patients (62 years old on median compared to 65), and those with Gleason 6 disease had a higher risk of prostate cancer death compared with nonblack patients. Black men with Gleason 6 prostate cancer had a two-fold increased risk of dying from prostate cancer compared to men from other racial/ethnic groups.

 

Read more at UCSF.edu